Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.RBC Capital Markets initiated coverage on Tandem Diabetes Care, Inc. (NASDAQ:TNDM), a global insulin delivery and diabetes technology company that manufactures and sells advanced automated insulin delivery systems.
RBC資本市場開始對Tandem Diabetes Care Inc.（納斯達克：TNDM）進行覆蓋，這是一家全球胰島素輸送和糖尿病科技公司，專門生產和銷售先進的自動化胰島素輸送系統。
The analyst highlights several key growth drivers for Tandem, positioning it for sustained growth over the coming years driven by expansion into the U.S. Type 1 market with a 40% pump penetration (Tandem has a one-third share), which is expected to rise to the mid-60s and Type 2 market with 6% penetration.
分析師強調了幾個Tandem的主要增長驅動因素，使其在未來數年內實現可持續增長，原因是其在美國1型糖尿病市場的擴張，其中40%的泵銷售（Tandem佔據三分之一的市場份額），預計將增加到中60%左右，以及2型糖尿病市場的6%滲透率。
The company is also seeking deeper penetration within existing accounts through product innovations.
該公司還通過產品創新尋求在現有帳戶中實現更深層次的滲透。
The analyst also added that the rise of GLP-1s class drugs is not a major threat to insulin pump adoption.
分析師還指出GLP-1類藥物的崛起不會對胰島素泵的採用構成重大威脅。
GLP-1 drugs such as Novo Nordisk A/S' (NYSE:NVO) semaglutide as Wegvoy and Ozempic and Eli Lilly And Co's (NYSE:LLY) tirzepatide as Zepbound and Mounjaro, have recently made waves.
GLP-1藥物，如諾和諾德公司（紐交所：NVO）的semaglutide（Wegvoy和Ozempic）和Eli Lilly And Co公司（紐交所：LLY）的tirzepatide（Zepbound和Mounjaro），最近引起轟動。
RBC analyst highlights that insulin is essential for insulin-dependent patients, as GLP-1 medications cannot regenerate beta cells or halt their deterioration. As a result, the need for insulin remains.
RBC分析師強調胰島素對於胰島素依賴患者至關重要，因爲GLP-1藥物無法再生β細胞或阻止其惡化。因此，對胰島素的需求仍然存在。
The Type 2 diabetes population, which suffers from irreversible beta cell loss, is underserved.
2型糖尿病人群，其β細胞喪失是不可逆的，因此未得到充分服務。
The growing popularity of GLP-1 drugs may lead to earlier diagnoses of Type 2 diabetes and prompt insulin use, potentially expanding the market.
GLP-1類藥物日益普及可能導致對2型糖尿病的早期診斷和促使使用胰島素，從而可能擴大市場規模。
RBC initiated Tandem with an Outperform, with a price target of $65, citing a significant upside potential driven by earning revisions and multiple expansions.
RBC啓動了Tandem業績評級爲Outperform，目標股價爲65美元，稱其盈利修訂和多重擴張驅動了顯著的上行潛力。
RBC sees an opportunity for Tandem to achieve profitability over time and projects gross margins of 51% in 2024 or flat y/y to reflect the Mobi launch and investments in several ongoing R&D initiatives.
RBC認爲Tandem有機會在未來實現盈利，並預計2024年毛利率爲51%，與去年持平，反映了Mobi的推出以及對幾項持續研發計劃的投資。
The analyst sees a clear path for the company to reach its goal of approximately 65% margins, with Mobi accounting for about half of that progress. Further gains are anticipated from planned initiatives.
分析師認爲公司實現約65%利潤率的目標有明確途徑，Mobi將貢獻約一半的進展。計劃中的舉措進一步增加了預期的收益。
RBC projects breakeven for 2024, with positive adjusted EBITDA margins expected in the second half of the year.
RBC預計2024年實現盈虧平衡，預計全年調整後的EBITDA盈利率將於下半年實現正值。
Price Action: TNDM stock is down 0.37% at $40.92 at the last check on Wednesday.
股價表現：上週三最近一次交易時，TNDm股價下跌0.37%，報40.92美元。
- Toyota Doubles Down On Joby Aviation: $500M Investment Powers US Electric Air Taxi Certification, Production.
- 豐田加大對Joby Aviation的投資力度：50000萬美元的投資支持美國電動空中出租車的認證和生產。
譯文內容由第三人軟體翻譯。
